~~<i id='E3216D9BF1'><strike id='E3216D9BF1'><tt id='E3216D9BF1'><pre id='E3216D9BF1'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：comprehensive 2025-09-29 09:24:00 Page View：6593

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates
Next article： In age of alternative facts, a scholarly course on calling out crap

leisure time

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Former medical device CEO who sold dummy, plastic parts convicted of fraud

BRENDANSMIALOWSKI/AFPviaGettyImagesANewYorkjuryonWednesdayconvictedtheformerCEOofStimwave,acompanyth

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Montana youths win climate lawsuit against state for promoting fossil fuels

0:45Supportersgatheratatheaternexttothecourthousetowatchthecourtproceedingsforthenation'sfirstyouthc